Viroclinics-DDL Revenue and Competitors
Estimated Revenue & Valuation
- Viroclinics-DDL's estimated annual revenue is currently $46.5M per year.
- Viroclinics-DDL's estimated revenue per employee is $155,000
Employee Data
- Viroclinics-DDL has 300 Employees.
- Viroclinics-DDL grew their employee count by -25% last year.
Viroclinics-DDL's People
Name | Title | Email/Phone |
---|---|---|
1 | Clinical Data Officer | Reveal Email/Phone |
2 | Compliance officer (QS) | Reveal Email/Phone |
3 | Quality Assurance Officer | Reveal Email/Phone |
4 | VP Legal | Reveal Email/Phone |
5 | Validation Officer | Reveal Email/Phone |
6 | LIMS support officer | Reveal Email/Phone |
7 | VP Business Development | Reveal Email/Phone |
8 | Quality Assurance Officer | Reveal Email/Phone |
9 | VP QA | Reveal Email/Phone |
10 | Purchase Officer | Reveal Email/Phone |
Viroclinics-DDL Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.5M | 300 | -25% | N/A | N/A |
What Is Viroclinics-DDL?
Viroclinics operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, research & development and clinical trial logistics services. Our extensive experience with clinical and preclinical studies for viruses, including our specialty in respiratory viruses, puts us at the forefront for supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. For more information, please visit: www.viroclinics.com / www.ddl.nl
keywords:N/AN/A
Total Funding
300
Number of Employees
$46.5M
Revenue (est)
-25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $71.6M | 318 | -3% | N/A |
#2 | $136.5M | 333 | 40% | N/A |
#3 | N/A | 334 | 13% | N/A |
#4 | $55.8M | 360 | 26% | N/A |
#5 | N/A | 392 | 18% | N/A |